Stay up-to-date with NeOnc's latest developments. Explore our latest news, official press releases, and in-depth research articles to follow our journey of innovation and stay informed about our progress and contributions to the field.
LATEST FROM NEONC
Our Latest Research & Study
Latest Studies
NEO100 Research Shows Impact On Recurrent Grade 4 Astrocytoma
Patients with grade 4 gliomas, particularly those experiencing recurrence, need better treatment options. Researchers are developing NEO100, a clinical-grade version of perillyl alcohol, a natural compound, to be delivered intranasally…
NEO100 Intranasal Delivery Technology Shows Promise for Better Therapeutic Results.
This paper discusses the need for better treatment options for patients suffering from astrocytoma and glioblastoma (GBM), the two most frequently diagnosed primary brain tumors. In addition, secondary brain cancers…
Study Shows NEO400 Has Therapeutic Effect On UV-Induced Skin Damage
A study conducted by NeOnc Technologies Holdings and published in the Wiley Online Research Library examined the effects of NeOnc’s NEO400 formulation for treating skin damage caused by prolonged ultraviolet…
NEO100 Enhances Entry And Therapeutic Activity Of Chimeric Antigen Receptor T Cells
In an article published in the Journal of Neurosurgery website, the study results were posted on Neonc Technologies Holdings’ recent animal study looking at the efficacy of using the NEO100…
Transfemoral Injection of NEO100 Provides Potential for Delivery of Therapeutics to the Brain
In an article published on the Oncotarget.com website, the use of transfemoral injection of NEO100 to provide entry for therapeutics into the brain is explored. The paper provides an overview…
Postsurgical Biopsy Shows Viability of NEO100 Intranasal Delivery
In a recent case trial follow up of a patient with a recurring glioblastoma (GBM) tumor who had been undergoing NEO100 intranasal treatment, a postsurgical biopsy of the tumor showed…
Latest Videos
Videos
Latest Press Releases
FROM THE PRESS ROOM
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous…
NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results
Insider buying indicates management’s conviction in undervalued shares ahead of multiple near-term catalysts: NEO100: interim data readout – expected within ~4 months NEO212: expects Type B End-of-Phase FDA meeting to…
NeOnc Provides Business Update and Reports Q4 2025 Financial Results
CALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous…
NeOnc Technologies Appoints David Choi as Chief Accounting Officer
CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous…
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management Hosted KOL Conference Call
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous…
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity
CALABASAS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous…
Latest News & Insights
FROM THE NEWS ROOM
Top Entrepreneurs Going into 2026
Publication Date: February 23, 2026 Published By: USA Today Article Link: https://www.usatoday.com/story/special/contributor-content/2026/02/23/top-entrepreneurs-going-into-2026/88825698007/ Entrepreneurship heading into 2026 looks very different from what it did even a few years ago. A look…
NeOnc Technologies: From Survival Mode To Expansion Mode
Summary NeOnc Technologies Holdings is a micro-cap biotech focused on innovative brain cancer treatments, NEO100 and NEO212, both in early clinical trials. NTHI’s financials are challenging, with no revenue, rising…
Building Biotech Excellence: The Growth Strategy Behind NeOnc Technologies’ Vision
Publication Date: March 13, 2025Published By: Venture BeatArticle Link: https://venturebeat.com/business/building-biotech-excellence-the-growth-strategy-behind-neonc-technologies-vision/ In his years as Director of Surgical Neuro-Oncology at the University of Southern California (USC), Dr. Thomas Chen has witnessed…
USC-licensed Startup NeOnc Technologies Celebrates NASDAQ Listing
Publication Date: March 27, 2025Published By: Healthcare ExecutiveArticle Link: https://www.healthcareexecutive.in/blog/usc-licensed-startup On Wednesday, a USC-licensed startup biomedical company and Keck Medicine of USC neurosurgeon focused on treating brain cancer are taking…
NASDAQ’S Opening Bell Will Ring For USC Research Startup
Publication Date: March 25, 2025 Published By: USC Today Article Link: https://today.usc.edu/nasdaqs-opening-bell-will-ring-for-usc-research-startup/ A USC-licensed startup biomedical company and a Keck Medicine of USC neurosurgeon focused on treating brain cancer are…
Pioneering a New Era in Brain Cancer Treatment with NASDAQ Listing
Publication Date: March 25, 2025 Published By: USC Today Article Link: https://healthcare360magazine.com/nasdaq-visionaries-neonc-technologies/ The landscape of healthcare is in a state of perpetual evolution, driven by relentless innovation and a desire…